Thermo Fisher Scientific Inc. $TMO Stake Boosted by Cohen Investment Advisors LLC

Key Points

• Cohen Investment Advisors LLC increased its stake in Thermo Fisher Scientific by 12.4% during the second quarter, bringing its total holdings to 6,650 shares valued at approximately $2.7 million.
• Several institutional investors, including Vontobel Holding Ltd. and Castle Rock Wealth Management LLC, also boosted their positions in the company, indicating strong institutional interest with 89.23% of the stock now owned by institutional investors.
• Thermo Fisher reported a quarterly EPS of $5.36, surpassing estimates, and has set its Q3 2025 EPS guidance between 5.460 and 5.510, reflecting solid financial performance.

Cohen Investment Advisors LLC grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,650 shares of the medical research company's stock after purchasing an additional 733 shares during the quarter. Cohen Investment Advisors LLC's holdings in Thermo Fisher Scientific were worth $2,696,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Vontobel Holding Ltd. grew its holdings in shares of Thermo Fisher Scientific by 4.5% during the second quarter. Vontobel Holding Ltd. now owns 1,089,103 shares of the medical research company's stock valued at $441,588,000 after purchasing an additional 46,743 shares during the last quarter. Maryland State Retirement & Pension System boosted its position in shares of Thermo Fisher Scientific by 2.8% during the second quarter. Maryland State Retirement & Pension System now owns 18,355 shares of the medical research company's stock worth $7,442,000 after buying an additional 496 shares during the period. Castle Rock Wealth Management LLC boosted its position in shares of Thermo Fisher Scientific by 10.9% during the second quarter. Castle Rock Wealth Management LLC now owns 3,545 shares of the medical research company's stock worth $1,457,000 after buying an additional 347 shares during the period. Navera Investment Management Ltd. boosted its position in shares of Thermo Fisher Scientific by 0.6% during the second quarter. Navera Investment Management Ltd. now owns 664,893 shares of the medical research company's stock worth $269,516,000 after buying an additional 3,675 shares during the period. Finally, Citizens National Bank Trust Department boosted its position in shares of Thermo Fisher Scientific by 4.4% during the second quarter. Citizens National Bank Trust Department now owns 5,097 shares of the medical research company's stock worth $2,067,000 after buying an additional 214 shares during the period. 89.23% of the stock is owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $536.21 on Thursday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The stock has a fifty day moving average of $486.09 and a 200-day moving average of $448.21. The company has a market capitalization of $202.48 billion, a PE ratio of 31.01, a price-to-earnings-growth ratio of 2.93 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the prior year, the firm earned $5.37 EPS. The company's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on TMO shares. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, October 4th. William Blair started coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They set an "outperform" rating for the company. Evercore ISI upped their target price on Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an "outperform" rating in a research report on Tuesday. Raymond James Financial restated an "outperform" rating and issued a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the stock an "outperform" rating in a research report on Tuesday, September 2nd. Fifteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $590.60.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.